CVRX INC (CVRX) Stock Price, Forecast & Analysis
NASDAQ:CVRX • US1266381052
CVRX Key Statistics, Chart & Performance
The current stock price of CVRX is 4.95 USD. In the past month the price decreased by -9.51%. In the past year, price decreased by -67.2%.
CVRX Technical Analysis
CVRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVRX. The financial health of CVRX is average, but there are quite some concerns on its profitability.
CVRX Financial Highlights
Over the last trailing twelve months CVRX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS increased by 23.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.73% | ||
| ROE | -108.26% | ||
| Debt/Equity | 1.03 |
CVRX Forecast & Estimates
13 analysts have analysed CVRX and the average price target is 11.73 USD. This implies a price increase of 136.97% is expected in the next year compared to the current price of 4.95.
For the next year, analysts expect an EPS growth of 3.82% and a revenue growth 15.28% for CVRX
CVRX Ownership
CVRX Latest News, Press Relases and Analysis
CVRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 195.936B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 172.536B | ||
| SYK | STRYKER CORP | 24.21 | 139.985B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 110.826B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 50.254B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.113B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.027B | ||
| RMD | RESMED INC | 20.57 | 36.792B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 36.615B | ||
| DXCM | DEXCOM INC | 27.73 | 27.309B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CVRX
Company Profile
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 206 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
Company Info
CVRX INC
9201 West Broadway Avenue, Suite 650
Minneapolis MINNESOTA US
CEO: Nadim Yared
Employees: 206
Phone: 17634162850
CVRX INC / CVRX FAQ
Can you describe the business of CVRX INC?
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 206 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
What is the current price of CVRX stock?
The current stock price of CVRX is 4.95 USD. The price decreased by -13.01% in the last trading session.
What is the dividend status of CVRX INC?
CVRX does not pay a dividend.
How is the ChartMill rating for CVRX INC?
CVRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about CVRX INC (CVRX) stock?
13 analysts have analysed CVRX and the average price target is 11.73 USD. This implies a price increase of 136.97% is expected in the next year compared to the current price of 4.95.
Is CVRX INC (CVRX) expected to grow?
The Revenue of CVRX INC (CVRX) is expected to grow by 15.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does CVRX INC have?
CVRX INC (CVRX) currently has 206 employees.